GLP-1 and the Nutrition Reset: How New Consumer Health Behaviors Are Reshaping Food, Beverage, and Personal Care
GLP-1 medications are quickly becoming one of the most important consumer behavior disruptors for food, beverage, nutrition, wellness, and adjacent personal care categories. The impact is not limited to fewer calories or smaller baskets. It is changing how consumers think about appetite, portion size, satiety, protein, fiber, hydration, digestive health, wellness routines, and the products they choose to keep in their homes.
A Journal of Marketing Research study using household transaction data found that grocery spending declined by 5.3% in the six months after GLP-1 adoption, with higher-income households reducing grocery spending by 8.2%. Cornell University described the work as one of the most comprehensive looks at how GLP-1 adoption is associated with changes in real-world food purchasing. At the same time, market reporting shows demand shifting toward fresh produce, protein, fiber, smaller portions, and nutrient-dense options.
For Consumer Products CEOs, the burning platform is that the demand signal is moving faster than many operating models can respond. Companies must adapt portfolios, sourcing, formulations, packaging, plant schedules, and channel strategies without creating complexity that destroys margin.
GLP-1 is not just shrinking consumption. It is reshaping what consumers value.
A Health Behavior Shift With Commercial Consequences
The GLP-1 effect is best understood as a broader health-behavior shift rather than a narrow pharmaceutical trend. Consumers using these medications often report reduced appetite, fewer cravings, and greater interest in foods and products that help them meet specific wellness goals with less intake. That shifts the value equation away from volume alone and toward functionality, portion control, nutrition density, and perceived support for a new lifestyle.
For food and beverage companies, this can affect snacks, sweets, baked goods, salty foods, sugary beverages, restaurant occasions, protein products, yogurt, fresh fruit, meal replacements, and supplements. For personal care and wellness-adjacent products, it can affect hydration, digestive health, skin care, fitness routines, body confidence, and convenience formats designed around new habits.
The opportunity is meaningful, but it is not automatic. Brands that simply add “high protein” or “GLP-1 friendly” language may not win if they cannot deliver taste, affordability, supply continuity, credible claims, and consistent availability. The winners will be those that understand the consumer behavior behind the medication and translate it into executable product and channel decisions.
Portfolio Speed Will Matter More Than Portfolio Size
GLP-1-driven behavior creates pressure to move faster on reformulation, pack architecture, ingredient sourcing, and product development. Smaller portions, higher protein, added fiber, lower sugar, gut-health benefits, hydration support, and nutrient density may all become more important depending on the category. But each of these shifts carries operational implications.
Protein and fiber claims may require different ingredients, supplier qualification, formulation stability, taste work, allergen management, quality controls, and labeling review. Smaller portions and new pack formats can affect packaging procurement, line speeds, changeovers, labor, minimum runs, and case configuration. A product that looks commercially attractive may be operationally expensive if it adds complexity without sufficient velocity.
Consumer Products companies therefore need a disciplined portfolio response. They need to know which categories are at risk, which products can be adapted, which new products deserve investment, and which SKUs should be simplified to make room for growth. Speed matters, but uncontrolled speed can create waste, write-offs, and plant instability.
The Supply Chain Behind the Nutrition Reset
The nutrition reset also affects supply. If demand shifts toward protein, fresh produce, yogurt, supplements, and functional ingredients, companies must assess whether suppliers can support the change at the required quality, cost, and volume. Business Insider has reported that protein demand is contributing to tight whey supplies, illustrating how quickly a consumer trend can become an input constraint.
This is particularly important for companies that depend on specialized ingredients, cold-chain logistics, fresh inputs, short shelf lives, or strict quality requirements. Forecast errors can become expensive quickly. Too little supply can result in lost shelf space and missed growth. Too much supply can create obsolescence, markdowns, waste, or working capital strain.
The operating model must therefore connect consumer insight to procurement and supply planning early. A demand shift is only valuable if the business can source, make, distribute, and replenish profitably.
Retailers Will Expect Faster Category Answers
GLP-1-driven demand shifts will not be managed by manufacturers alone. Retailers will ask which categories are at risk, which assortments need more functional choices, which pack sizes fit changing occasions, and which brands can help the retailer grow baskets even as some consumption occasions decline. That creates a new level of pressure on category management and customer teams.
Consumer Products companies need to show retailers that they understand the economics of the new consumer. A manufacturer should be able to explain how a product supports a changing basket, where it fits in the store or digital shelf, what it replaces, how it affects margin mix, and how the supply chain will support it. Without that discipline, the category conversation can be taken over by faster-moving competitors or retailer-owned alternatives.
The implication for leadership is clear: GLP-1 response should not be treated as a series of isolated launches. It should be managed as a cross-functional growth and risk agenda connecting consumer insight, portfolio strategy, supply readiness, manufacturing capability, retailer execution, and financial performance.
The Brooks International Perspective
From Brooks International’s perspective, GLP-1 is a demand disruption that must be managed through operating discipline. It is not enough to identify that consumers are buying differently. Consumer Products companies need to convert that insight into profitable, executable change across the business.
That means creating tighter linkage among category strategy, R&D, procurement, manufacturing, quality, packaging, sales, and supply planning. It means managing portfolio moves through fact-based governance: which opportunities improve growth and margin, which add complexity, which require new supplier capacity, and which can be scaled using existing assets.
It also means building scenario plans around adoption rates, discontinuation rates, income segments, and category exposure. Some shifts may accelerate quickly; others may prove temporary or uneven. The operating model needs enough flexibility to respond without overcommitting capital, inventory, or plant capacity to a demand signal that may evolve again.
Brooks International believes the companies that benefit most from this shift will be those that can pivot quickly without losing control. They will adjust product architecture, line schedules, sourcing strategies, and channel plans while maintaining service, cost discipline, quality, and cash performance.
The most attractive opportunities may not be the most obvious trend-chasing ideas. They may come from improving commercialization speed, reducing low-value complexity, increasing forecast accuracy, strengthening supplier readiness, and ensuring that innovation translates into measurable contribution rather than just more activity.
What Consumer Products Leaders Should Be Asking Now
The leadership agenda should focus on whether the business can adapt to GLP-1-driven behavior shifts while protecting margin and operational stability:
• Which categories, occasions, pack sizes, and consumer segments are most exposed to GLP-1-driven changes in appetite, portion size, and nutrition priorities?
• Where are consumers shifting toward protein, fiber, fresh, functional, or smaller-portion products, and can the company serve that demand profitably?
• Which product changes require new ingredients, suppliers, packaging, line configurations, or quality controls?
• Does the innovation process move fast enough to respond without overloading plants, suppliers, or working capital?
• Where should the business simplify the existing portfolio to create capacity for higher-value growth?
• Are claims, labeling, product performance, and consumer communication being governed with enough discipline to protect trust?
• Does leadership have an integrated view of demand risk, supply readiness, manufacturing constraints, and channel execution?
These questions matter because GLP-1 is changing consumption in ways that cut across product development, manufacturing, sourcing, and commercial execution.
The Leadership Imperative
GLP-1 medications are changing the consumer products landscape by altering appetite, food choices, wellness priorities, and expectations for products that deliver more benefit with less consumption. The impact will not be uniform across categories, but it will be significant enough that leaders cannot treat it as a niche issue.
For CEOs and boards, the mandate is to move faster without creating chaos. Consumer Products companies need the structure to sense demand shifts, test and scale the right products, protect supply, manage complexity, and convert health-driven behavior change into profitable growth.
The immediate opportunity is to make the organization more responsive without becoming more chaotic. Leaders should identify which demand shifts require action now, which require monitoring, and which would add complexity without enough return.
The winners will not be those that react with the most product claims. They will be those that build the operating capability to adapt with speed, discipline, and measurable results.
